Analysis of the clinical value of salvianolate combined with Xinmaitong capsule in the treatment of patients with unstable angina pectoris of coronary heart disease with electrocardiogram changes
Objective To explore the therapeutic value of salvianolate combined with Xinmaitong capsule in the treatment of patients with unstable angina pectoris of coronary heart disease with electrocardiogram changes.Methods 80 patients with unstable angina pectoris of coronary heart disease with electrocardiogram changes were selected as the subjects of this study.They were randomly divided into an observation group and a control group using a number table method,with 40 cases in each group.The control group was treated with conventional drugs,including myocardial nutrition,vasodilation,antiplatelet therapy,anticoagulation,and the use of salvianolate.The observation group was treated with Xinmaitong capsules on the basis of the control group.Both groups were compared in terms of treatment effect,plaque stability[i.e.,serum lipoprotein-associated phospholipase A2(Lp-PLA2)],left ventricular function indicators[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)],and lipid indicators(total cholesterol,triglycerides,low density lipoprotein cholesterol,high density lipoprotein cholesterol)before and after treatment,and the occurrence of adverse reactions.Results The total effective rate of the observation group was higher than that of the control group,with a total effective rate of 80.00%in the control group and 95.00%in the observation group,with a significant difference(χ2=4.114,P=0.043<0.05).Compared with that before treatment,Lp-PLA2 in both groups decreased after treatment,and the LP-PLA2 of(20.76±3.93)µg/L in the observation group was lower than(36.34±4.42)µg/L in the control group,with a significant difference(P<0.05).Compared with those before treatment,LVEF levels in both groups were increased after treatment,and the observation group[(49.89±3.07)%]was higher than the control group[(46.26±3.22)%];the levels of LVEDD and LVESD decreased,and the levels of the observation group were(51.83±3.66)and(35.87±3.41)mm,which were lower than(56.28±3.78)and(39.72±3.30)mm of the control group,with a significant difference(P<0.05).Compared with those before treatment,the levels of total cholesterol,triglyceride and low-density lipoprotein cholesterol in both groups were decreased after treatment;those in the observation group were(5.22±1.04),(1.57±0.08),(3.02±1.46)mmol/L,which were lower than those of(5.79±1.43),(2.24±0.23),(4.23±1.07)mmol/L in the control group;the level of high density lipoprotein cholesterol of(1.40±0.29)mmol/L in the observation group was higher than that of(0.99±0.05)mmol/L in the control group,with a significant difference(P<0.05).The incidence of adverse reactions was 5.00%in the control group and 7.50%in the observation group,and there was no significant difference between the two groups(χ2=0.213,P=0.644>0.05).Conclusion The combination of salvianolate and Xinmaitong capsule in the treatment of patients with unstable angina pectoris of coronary heart disease with electrocardiogram changes has a prominent effect,which is not only conducive to improving plaque stability,but also can improve cardiac function and blood lipids in patients with high safety,and is worthy of promotion and application.
Unstable angina pectorisCoronary heart diseaseChanges in electrocardiogramSalvianolateXinmaitong capsule
万方数据
维普
